SGSebnem Gursoy

Sebnem Gursoy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sebnem Gursoy has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the relationship between Hoffa volume and radiological and clinical scoring in the diagnosis and treatment of anterior knee pain: A retrospective observational study

    by Siddik Göksel Gürsoy, Ahmet Emrah Açan, Serdar Sargin, Özgür Baykan, Sercan Tosun, Erdoğan Bülbül

    This study aimed to evaluate the relationship between clinical outcomes and Hoffa fat pad (HFP) volume with respect to treatment type: conventional therapy (NSAIDs and topical cold) and intra-articular platelet-rich plasma (PRP). This retrospective study included patients aged 18 to 40 years with anterior knee pain (AKP), positive Hoffa squeeze and extension impingement tests, and no radiological pathology. After applying the inclusion and exclusion criteria, the patients were divided into conventional treatment (n = 28) and PRP (n = 27) groups, with a control group (n = 25) to compare the baseline HFP volume. HFP volume was measured pre- and posttreatment using 3D Slicer software, while clinical outcomes were assessed using Lysholm, Oxford Knee, and visual analog scale (VAS) scores. Baseline HFP volumes did not differ significantly between the groups (P = .236). The conventional group showed a significant reduction in HFP volume, from 30.8 ± 5.9 cm3 to 29.5 ± 5.7 cm3 (P = .002), while the PRP group saw an increase from 28.0 ± 5.3 cm3 to 29.9 ± 6.3 cm3 (P = .001). Baseline VAS scores were higher in the PRP group (7.1 ± 0.9 vs 6.0 ± 1.0, P < .001), with posttreatment VAS scores improving in both groups (PRP: 3.0, P < .001; Conventional: 1.5, P < .001). Lysholm and Oxford scores increased significantly posttreatment (P < .001), although no correlation was found between HFP volume and these scores. These findings suggest Hoffa volume may influence AKP, although volume changes do not directly correlate with functional improvement, indicating that other pathophysiological factors may play a role. These findings highlight the need for further studies to understand HFP’s role of HFP in AKP and inform targeted treatments.


  • Endoscopic Topical Application of Ankaferd Blood Stopper ® in Gastrointestinal Bleeding

    by Ahmet Karaman, Mevlut Baskol, Sebnem Gursoy, Edip Torun, Alper Yurci, Mehmet Çelikbilek, Kadri Guven, Omer Ozbakir, Mehmet Yucesoy

    Aim: This was a prospective study investigating the efficacy of Ankaferd Blood Stopper® (ABS), an herbal preparation, in patients with upper gastrointestinal (UGI) bleeding. Materials and methods: A total of 30 patients (22 male, 8 female) who had UGI bleeding (with differing causes) were included in the study. ABS was used to stop the bleeding. Results: Primary hemostasis was achieved in 26 of the 30 cases. Conclusions: ABS is an effective and safe agent to use in patients with UGI bleeding.


  • Efficacy of Ankaferd Blood Stopper in Postpolypectomy Bleeding

    by Ahmet Karaman, Edip Torun, Sebnem Gürsoy, Alper Yurci, Ömer Özbakır


  • Open Access

    Occult HBV Infection in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients

    by Tansu Sav, Sebnem Gursoy, Edip Torun, Nadide Melike Sav, Aydin Unal, Oktay Oymak, Cengiz Utas

    Aim. Occult hepatitis B virus (HBV) infection can be defined as the presence of HBV DNA in the liver and/or blood in the absence of detectable serum hepatitis B surface antigen (HBs Ag). There is a high prevalence of occult HBV infection in dialysis patients. This study investigated the prevalence of occult HBV infection in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients and compared the prevalence of occult HBV infection in dialysis patients either with or without hepatitis C virus (HCV) infection. Methods. In this cross-sectional study, 71 CAPD patients and 71 HD patients were evaluated. HBV DNA testing was performed by polymerase chain reaction (PCR). We recorded general characteristics of the patients, duration of dialysis, HBs Ag, antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), anti-HCV antibody (anti-HCV), HCV RNA, serum alanine aminotransferase (ALT), and aspartate aminotransferase levels (AST). Results. Twelve (16.9%) of the 71 HD patients and seven (9.8%) of the 71 CAPD patients were HBV DNA-positive. A statistically significant difference was not observed in the groups. Anti-HCV was negative and AST and ALT levels were normal in all of the HBV-DNA positive patients. Viral loads were low in both groups. Conclusion. This is the first study that analyzes occult HBV prevalence in CAPD patients. We conclude that the prevalence of the occult HBV may be common in CAPD patients as in HD patients, and HCV positivity is not a contributing factor to occult HBV infection in dialysis patients.